KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Enterprise Value (2016 - 2025)

Rigel Pharmaceuticals has reported Enterprise Value over the past 16 years, most recently at -$155.0 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 100.4% year-over-year to -$155.0 million; the TTM value through Dec 2025 reached -$155.0 million, down 100.4%, while the annual FY2025 figure was -$155.0 million, 100.4% down from the prior year.
  • Enterprise Value for Q4 2025 was -$155.0 million at Rigel Pharmaceuticals, down from -$137.1 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$39.3 million in Q1 2021 and troughed at -$155.0 million in Q4 2025.
  • A 5-year average of -$87.7 million and a median of -$77.2 million in 2024 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: surged 58.98% in 2021 and later tumbled 173.27% in 2022.
  • Year by year, Enterprise Value stood at -$125.0 million in 2021, then surged by 53.42% to -$58.2 million in 2022, then grew by 2.19% to -$56.9 million in 2023, then crashed by 35.81% to -$77.3 million in 2024, then tumbled by 100.4% to -$155.0 million in 2025.
  • Business Quant data shows Enterprise Value for RIGL at -$155.0 million in Q4 2025, -$137.1 million in Q3 2025, and -$108.4 million in Q2 2025.